Breast Cancer Clinical Trial
Official title:
Promoting Post-traumatic Growth in Cancer Patients: a Study Protocol for a Randomized Controlled Trial of Guided Written Disclosure
This study aims to investigate the efficacy of Guided Written Disclosure Protocol (GWDP) in promoting post-traumatic growth through a process of meaning reconstruction in cancer patients at the end of chemotherapy. Also, the intervention (GWDP) intends to reduce distress symptoms (i.e. intrusive thoughts, avoidance, depression and anxiety).
Study aims The primary aim of this study is to assess the efficacy of the Guided Written
Disclosure Protocol in promoting post-traumatic growth in stage I-III breast and colon
cancer patients at the end of their adjuvant chemotherapy.
The secondary aims of the study include
- Evaluating the efficacy of the GWDP in terms of intrusive thoughts and avoidance
reduction
- Assessing the efficacy of the GWDP in terms of reduction of depression and anxiety
- Investigating the relationship between constructed meaning and post-traumatic growth.
Methods Study design The study is a randomized controlled trial. Eligible patients who give
their consent to participate in the study will be randomized to receive the GWDP
intervention (experimental group) or a control intervention (control group).
Participants Participants will be recruited in the Oncological Day Hospitals (DH) of the
Scientific Research and Care Institute (IRCCS) Santa Maria Nuova Hospital of Reggio Emilia -
Oncology Unit
Eligibility criteria will be assessed by reviewing the patients' medical record and verified
at the time of recruitment.
Randomization Eligible patients, who agree to participate in the study, will be randomly
assigned to the GWDP condition or to the control condition with an allocation ratio 1:1,
stratified by the oncological DH. Randomization is carried out through a central phone
randomization center using computer generated random numbers.
After the registration of the patient basic information, the trial center will attribute a
unique code to the included patient, and communicate to the professional the allocated
condition. This code will be reported in all the forms related to each patient.
The interventions The experimental intervention (GWDP) consists of three 20-minutes writing
sessions in which instructions are provided to patients that have experienced the traumatic
event of cancer diagnosis and therapies. Initially, participants are invited to recall
chronologically the facts concerning the traumatic event, and then to label the emotions
related to those facts, appraise immediate changes in priorities, reflect on their current
feelings, and on coping mechanisms they have learned. Moreover, they are asked to reflect on
how the experience of cancer has changed their view about life and themselves, teaching them
to cope with other difficulties that may arise in the future.
Below, investigators report a synthesis of the tasks concerning each of the three writing
sessions. Participants are asked to:
1. describe memories concerning cancer illness in a chronological order, with an objective
and detached attitude.
2. describe: (a) thoughts and emotions perceived during the illness experience; (b) the
impact of illness on their daily lives, and how it has changed their attitudes toward
life.
3. focus on their actual situation, think about the entire illness experience, and report
on the following aspects:
- their present thoughts and feelings, and how those differ from the ones felt
during the illness experience.
- to what extent they have come to terms with, understand and appreciate themselves
to have dealt successfully with the illness.
- what they have learned from illness in terms of personal insights, knowledge and
skills, and how these resources could be useful in their future.
- how they will cope with other similar events in the future.
Participants are asked to find a quiet place and time in their home to write without being
disturbed. The first writing session will be performed by two weeks from the initial
assessment (T0), and the following two sessions once every two weeks.
Original instructions were translated into Italian, and adapted to the specific traumatic
experience of cancer diagnosis and treatment.
The control condition consists of three 20-minutes writing sessions in which participants
are requested to write about events of their daily routine happened during the past week;
they are also asked to focus on facts, with an objective and detached attitude. An active
control intervention is used to account for both general (i.e., due to a written general
description) and specific effects (i.e., due to a written emotional expression, together
with a cognitive reframing) of the writing task.
As for the experimental group, participants are asked to find a quiet place and time to
write without being disturbed. It was used the same time interval between sessions as for
the GWDP.
One day before each writing session, patients in both conditions will be contacted on the
telephone by the researcher, who will check their understanding of instructions included in
the booklet, and remind them to perform the writing task. Failure to contact the patient
will be recorded in the patient form.
Procedures of recruitment and assessment Recruitment and baseline assessment (T0). One or
more health care professionals (oncologists, nurses or psychologists) will participate as
recruiters and evaluators. They will be trained by the Steering Committee about study aims
and procedures, and provided with study materials. The preferred method of recruitment
involves the oncologist in informing eligible patients, who attend DH for their medical
consultation. In case of impediments to recruitment (e.g., oncologists' lack of motivation
for involvement in the study, medical consultation scheduled beyond eight months after the
end of chemotherapy, patients' unavailability at the time of medical appointment), a letter
will be sent to eligible patients presenting general information about the study. Three to
seven days later, a member of the study staff will call the patient by phone to give further
information, and to verify his/her availability to participate.
Patients interested in the intervention will meet a health care professional, who will
explain both the study aims and the writing tasks, providing them with the information
sheet, and collecting socio-demographic data and health information (i.e., age, sex,
educational level, marital status, time since diagnosis, disease site and stage, and
treatment received). Patients, who agree to participate, will give their written consent.
The health care professional will administrate baseline questionnaires, and then will
contact the trial center for randomization. Finally, the booklet concerning the
intervention, according to allocation group, will be provided to the participant. Anonymity
will be guaranteed for both written texts and outcomes assessment.
Post-intervention and follow- up assessments (T1 and T2). Participants will be re-assessed
for the study outcomes three months after baseline (T1), with a time tolerance of ± 15 days,
whenever is possible during any medical consultation. In this occasion, the booklet
containing the patient's written texts will be returned. Follow-up evaluation (T2) will be
performed six months after the post-intervention assessment (with the same time tolerance of
± 15 days), whenever is possible during any medical consultation.
Hypotheses Main hypothesis. Investigators expect that, after the intervention, participants
in the GWDP group will have higher scores on the Post-Traumatic Growth Inventory as compared
to the control group.
Meaning construction is deemed as the mechanism underlying the restructuring of more
adaptive schemas that lead to growth. Therefore, investigators expect that increased levels
of PTG could be moderated by constructed meaning, measured by the Constructed Meaning Scale.
Secondary hypothesis. Investigators hypothesize that, after the intervention, participants
in the GWDP group will have lower scores on the Impact of Events Scale as compared to the
control group. Investigators also predict that participants in the GWDP group will have
lower scores on the Hospital Anxiety and Depression Scale as compared with the control
group.
Sample size A prospective power analysis revealed that the current study would require 250
participants to achieve 80% power. The predicted effect size (Hedges's g = 0.36) is
estimated according to a recent meta-analysis on the effect of psychological interventions
on post-traumatic growth.
Data analysis A preliminary analysis will be performed to compare, at baseline, the
differences of clinical and demographic data between the two groups (GDWP intervention vs.
control intervention). After that, a 2 X 3 mixed factorial design ANOVA will be performed
for each dependent variable (Post-traumatic growth, and distress measures). The "between"
factor is intervention with two levels (yes/no) and the "within" factor is time with three
levels (T0/T1/T2). Adjusted analysis of variance with sociodemographic and health variables
as covariant will be performed. Finally, the potential moderating role of constructed
meaning on the effect of GWDP will be according to the MacArthur approach.
Ethical issues The data collection and the intervention will be performed in accordance with
the ethical standards of the local Ethical committee, which have approved the protocol.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
| Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
| Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
| Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
| Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
| Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
| Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
| Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
| Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
| Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
| Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
| Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
| Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
| Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
| Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
| Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
| Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
| Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A |